FSTL3 and its role in mediating fibrosis and hypertrophy in diet-induced obesity by Long, William
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
FSTL3 and its role in mediating
fibrosis and hypertrophy in
diet-induced obesity
https://hdl.handle.net/2144/16818
Boston University
	BOSTON UNIVERSITY 
 
SCHOOL OF MEDICINE 
 
 
 
 
 
 
Thesis 
 
 
 
 
 
 
FSTL3 AND ITS ROLE IN MEDIATING FIBROSIS AND HYPERTROPHY IN 
DIET-INDUCED OBESITY 
 
 
 
 
by 
 
 
 
WILLIAM LONG 
 
B.S., Regis University, 2012 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of  
 
Master of Science 
 
2016  
	 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© 2016 by 
WILLIAM LONG 
All rights reserved  
	 
Approved by 
 
 
 
 
First Reader   _____________________________________________________  
Wilson S. Colucci, M.D. 
Professor of Medicine 
 
 
 
 
 
 
Second Reader  ___________________________________________________ 
Isabel Dominguez, Ph.D. 
Assistant Professor of Medicine  
    
  
 
 
 
 
 
 
 
 
 
 
 
 
	 iv	
FSTL3 AND ITS ROLE IN MEDIATING FIBROSIS AND HYPERTROPHY IN 
DIET-INDUCED OBESITY 
WILLIAM LONG 
ABSTRACT 
Metabolic syndrome (MetS) is a conglomeration of several risk factors for 
cardiovascular disease, with obesity currently being one of the common causes 
of disability and death in the United States.1 Underlying the obesity, however, 
there is metabolic imbalance that could be exacerbating the issue of metabolic 
syndrome.2 Approximately 34% of adults over 20 years old matched the criteria 
for metabolic syndrome.3 The risk factors for cardiovascular disease (CVD) 
associated with metabolic syndrome can, over time, lead to severe CVDs, such 
as heart failure (HF).4 Metabolic syndrome can also lead to developing metabolic 
heart disease over time. Understanding the development of cardiac hypertrophy 
and fibrosis in diet-induced metabolic heart disease allow development of an 
early treatment of metabolic heart disease (MHD) and HF. 
This study looked at one potential mediator and its role in cardiac 
hypertrophy and fibrosis, follistatin-like 3 (FSTL3). FSTL3 is an extracellular 
antagonist of members of the TGF-β superfamily. The goal of our study was to 
determine the effect, if any, a knockout of FSTL3 would have on the development 
of cardiac hypertrophy and fibrosis after a high-fat, high-sucrose diet for five 
months. FSTL3 knockout mice were given a high-fat, high-sucrose (HFHS) diet 
for five months. These mice were then sacrificed and their hearts were analyzed 
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for cardiac myocyte hypertrophy and interstitial fibrosis using histological 
methods. After five months on the HFHS diet, wild-type (WT) mice had cardiac 
hypertrophy. In FLRG KO mice the diet-induced cardiac hypertrophy was 
attenuated. WT HFHS-fed mice developed interstitial fibrosis, and FLRG KO 
HFHS developed more accentuated interstitial fibrosis than WT HFHS diet fed 
mice. This study is useful in suggesting that FTSL3 contributes to the 
pathogenesis of cardiac hypertrophy in MHD. FTSL3 may be a useful biomarker 
for cardiac hypertrophy in patients with suspected MHD, and may be a viable 
target for therapeutic interventions aimed at decreasing pathologic myocardial 
hypertrophy.  
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INTRODUCTION 
Metabolic Syndrome and Heart Failure 
 
Metabolic syndrome (MetS) is a conglomeration of several risk factors 
(Table 1) for cardiovascular disease including elevated glucose concentrations in 
the fasting state (≥100 mg/dL), high systolic (≥ 130 mmHg) or diastolic (≥ 85 
mmHg) blood pressure, high triglycerides (≥ 150 mg/dL), low values of high-
density lipoprotein (≤ 40 mg/dL in men and ≤ 50 mg/dL in women), and 
abdominal obesity (waist circumference of ≥40 inches in men and ≥35 inches in 
women).4,5  
 
Table 1. Adult values for the diagnosis of metabolic syndrome. To be 
diagnosed with metabolic syndrome, a patient must display at least three 
of the symptoms listed in the table.6  
 
Risk Factor Defining Level 
Abdominal obesity, given as waist 
circumference*† 
 
    Men >102 cm (>40 in) 
    Women >88 cm (>35 in) 
Triglycerides ≥150 mg/dL 
HDL cholesterol  
    Men <40 mg/dL 
    Women <50 mg/dL 
Blood pressure ≥130/≥85 mm Hg 
Fasting glucose ≥110 mg/dL‡ 
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Obesity, in particular, has reached an unfathomable prevalence in the 
United States. In fact, obesity is one of the common causes of disability and 
death in the U.S., and the prevalence of obesity in various subgroups of the 
population, such as youth and people of a lower socioeconomic status, has 
increased in recent years.1 Underlying the obesity, however, there is metabolic 
imbalance that could be exacerbating the issue of metabolic syndrome.2 
Approximately 34% of adults over 20 years old matched the criteria for metabolic 
syndrome.3 The risk factors for cardiovascular disease (CVD) associated with 
MetS can, over time, lead to severe CVDs, such as heart failure (HF).4 This is 
shown in individuals with MetS and their 2-fold higher chance of developing CVD 
than their healthy counterparts.7 In addition, over time, the risk of heart failure for 
obese individuals goes up dramatically (Figure 1).  
Heart failure is capable of reducing cardiac output and limiting the delivery 
of oxygenated blood to the tissues, while also causing an accumulation of blood 
in the venous system.8 It is also strongly associated with high mortality rates. 
According to the Heart Disease and Stroke Statistics report from the American 
Heart Association, 1 in 9 death certificates in 2011 mention heart failure and of 
those, heart failure was the underlying cause of death in 20% of them.1 The high 
medical costs and increasing prevalence of heart failure demands that a new 
method of detection be put in place to ensure timely diagnosis and early 
treatment to avoid the mortality associated with HF. 
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Figure 1. Cumulative incidence of HF in normal vs. obese patients. 
Over time, the incidence of HF in obese subjects goes up drastically. This 
exemplifies why a further knowledge of the biochemistry of the 
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development of heart failure as a result of obesity occurs. Figure from 
Kenchaiah et al. 2002.9 
 
Cardiac Hypertrophy and Fibrosis 
 
MHD is marked by LVH, myocardial fibrosis, diastolic dysfunction, and 
impaired cardiac energetics.10–12 Similarly, it has been shown in animal models 
that pressure overload through transverse aortic constriction (TAC) induces left 
ventricular hypertrophy (LVH) and cardiac remodeling and fibrosis.13 While the 
TAC model is seemingly a severe model of heart failure, metabolic syndrome 
develops much more slowly. 
To understand the development of fibrosis, a background of collagen 
production is necessary. The structure of the myocardium consists of myocytes, 
fibroblasts, endothelial cells, and smooth muscle cells; the extracellular matrix 
(ECM) is composed of collagen fibers, elastin fibers, proteoglycans, among other 
important proteins.14 The primary types of collagen present in the myocardial 
ECM consists of type I and type III collagen fibers. During the formation of 
collagen fibers, a procollagen (a mature collagen precursor) is secreted into the 
ECM, and is then cleaved by endopeptidases. These new collagen fragments 
condense together to form collagen fibrils. Fibrosis occurs when there is a 
disruption in the metabolism and breakdown of collagen fibrils.15 
There are two separate, but related, methods of fibrotic remodeling: 
reparative and reactive.16 Generally in instances of cardiac injury, the heart 
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needs to repair itself using scar tissue in instances of cell death, such as 
ischemia. On the other hand, reactive fibrosis is remodeling of the interstitial 
space in response to increased demand on the heart, such as is present with 
hypertension and cases without extensive cell damage, as in MHD.17 The 
accumulation of unneeded collagen fibers in the interstitial matrix to a pathologic 
level has been attributed to contributing to the onset of diastolic dysfunction.18 
Diastolic dysfunction has no cure, and contributes to morbidity and mortality at an 
astonishing rate. Only five years after the diagnosis of moderate to severe 
diastolic dysfunction (DD), there is more than a 20% mortality in patients (Figure 
2).19  
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Figure 2. Mortality associated with diastolic dysfunction. Even five 
years after the diagnosis of diastolic dysfunction, moderate to severe DD 
has more than a 20% mortality rate compared to that of a patient with 
normal diastolic function. From Redfield MM et al. 2003.19 
 
High fat, high sucrose diet as a model for metabolic syndrome 
A HFHS diet used in animal models has been shown to duplicate the 
symptoms of metabolic syndrome in humans.10,12,20–22 Using the three-symptom 
requirement for diagnosis in humans, metabolic syndrome can also be crudely 
diagnosed in mice. Mice on a HFHS diet develop obesity,10 insulin resistance 
leading to high fasting plasma glucose levels,21 and high blood pressure.20,21 In 
addition, a HFHS diet led to tissue-specific changes in the heart such as 
LVH,10,20 chronic inflammation,21 diastolic dysfunction,10,12,20 and cardiac 
interstitial fibrosis.12,20  
Another mediator of cardiac hypertrophy and fibrosis as a result of a 
HFHS diet is reactive oxygen species (ROS). After only four months on a HFHS 
diet, mitochondrial function declined, LVH developed, and ROS production 
increased.10 The effect of ROS on the cardiac structure and function has been 
studied previously. If the effect of ROS is negated with either a polyphenol with 
antioxidant effects or an enzyme to reduce the amount of ROS present, the 
cardiac structural changes are prevented.10,20 
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Cardiokines 
 Much like other tissues, the heart is capable of releasing extracellular 
proteins in the interstitial space and the bloodstream. These proteins have the 
potential to communicate in normal cellular growth as well as a reaction to 
pathological activities occurring in the body. In the heart, these secreted proteins 
are known as cardiokines. With the increasing prevalence of obesity and heart 
disease, there is an increasing desire to identify new biomarkers for early 
diagnoses as well as potential targets for therapeutics.23 In addition, cardiokines 
are capable of playing a role in pathologic cardiac remodeling through processes 
like fibroblast stimulation and apoptosis or even have a contributing role in 
muscle wasting processes.23 
 Currently, levels of B-type natriuretic peptide (BNP) present in circulation 
are the gold standard to help in the diagnosis of HF; however, in patients with 
diastolic dysfunction or heart failure with preserved ejection fraction (HFpEF), the 
sensitivity of BNP tests have been brought into question.24 As such, new 
biomarkers in models of MetS or diastolic dysfunction are needed for early 
diagnosis. 
 
Transforming Growth Factor β 
 
The transforming growth factor beta family (TGF-β) consists of pleiotropic 
cytokines which is involved in many aspects of cellular functions, spanning from 
cell growth, proliferation, and differentiation to inflammation and ECM protein 
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deposition.25,26 Three isoforms of TGF-β are encoded in mammals, which include 
TGF-β1, TGF-β2, and TGF-β3. These glycoproteins are secreted into the ECM 
as an inactive complex with latency associated peptide (LAP). This inactive 
secretion prevents the immediate binding and activation of TGF-β receptors. 
Enzymes such as plasmin and cathepsin, or substances such as reactive oxygen 
species can activate TGF-β.25,27 Once this complex is cleaved, the protein is 
active. 
There are many possible pathways towards cardiac remodeling, such as 
TGF-β, the renin-angiotensin-aldosterone system (RAAS), and activin A.15 One 
method of fibrosis and hypertrophy that has been heavily studied is the 
transforming growth factor beta (TGF-β) pathway.25 A TGF-β superfamily 
member will bind to the extracellular region of the type II receptor (TβRII), which 
then combines with and phosphorylates the type I receptor (TβRI). This complex 
initiates signalling through Smad-dependent and Smad-independent pathways as 
show in Figure 3. The activated receptor complex recruits the receptor-activated 
(R-) SMADs 2/3 or SMAD 1/5. This complex then binds with Smad 4 which 
allows the complex to translocate to the nucleus and interact with either co-
activators or repressors.  
TGF-β1 is known to have effects on the function of every cell in tissue 
injury, repair and remodeling; this includes cardiomyocytes and fibroblasts. 
Through TGF-β1 signaling, there is upregulation of ECM protein expression, 
such as collagen types I and III; there is inhibition of tissue inhibitors of 
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metalloproteinases (TIMPs), which inhibit the breakdown of collagen fibrils 
leading to more interstitial fibrosis; and there is hypertrophy of the 
cardiomyocytes.25 To test TGF- β1’s impact in the heart further, Lijnen PJ et al. 
found that providing neutralizing TGF-β1 antibodies in vivo prevented the 
increase of ECM protein expression and reduces the amount of myocardial 
fibrosis.28 
 
 
Figure 3. Effects of TGF-β signaling. TGF-β signaling influences several 
key events in the production of cardiac fibrosis. The downregulation of 
MMPs and upregulation of TIMPs inhibits the degradation of excess 
collagen fibrils, it encourages fibroblast proliferation, and increases ECM 
protein deposition. From Biernacka A et al. 2011.29  
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Protective members of the TGF- β family 
 
Two members of the TGF-β family are myostatin and activin A. Both of 
these ligands send signals through SMAD 2 and SMAD 3 intracellular signaling 
and are negative regulators of cellular growth.13 Working through SMADs 2/3, 
myostatin inhibits the differentiation and hypertrophy of skeletal myotubes.30 The 
inhibition of skeletal muscle growth can lead to cachexia, or muscle wasting 
disease, which increases the risk of HF.31  
Both myostatin and activin A, on the other hand, are capable of 
attenuating cardiac hypertrophy in vitro, and activin A transcript levels rise in 
cases of congestive heart failure.13 Activin A is capable of protecting 
cardiomyocytes from hypoxia/reoxygenation-induced apoptosis in vitro and also 
protected cardiac tissue from ischemia/reperfusion injury.32 In addition, it has 
been shown that activin A limits the hypertrophic response of cardiomyocytes in 
vitro, but that suppression is reversed with overexpression of follistatin-like 3 
(FSTL3).23 It is believed that overexpression of FSTL3 results in excess binding 
of activin A, leading to decreased activation of the cardioprotective SMAD2/3.23  
 
FSTL3 and its Role in Cardiac Hypertrophy and Fibrosis 
 Follistatin-like 3 (FSTL3) is a member of the follistatin family, a group of 
extracellular glycoproteins which antagonize the effects of the members of the 
TGF-β family, such as the cardioprotective activin A and myostatin.33 Once a 
member of the TGF-β family binds to its receptor, the Smad signaling cascade 
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transcriptionally regulates the expression of FSTL3 to provide a negative 
feedback loop for TGF-β.34 Follistatin (FST) and FSTL3 are similar in both 
structure and function. However, these two extracellular regulators differ in their 
expression distribution. While FST expression is highest in the ovary, testes, and 
kidney, FSTL3 expression is preferentially expressed in the heart.13,35  
 Genetic ablation of follistatin-related gene (FLRG), the gene that encodes 
for the FSTL3 glycoprotein, has already been studied in a full-body over-
expression and knockout models.35,36 In the full-body over-expression model, 
following a high-fat diet over 12 weeks, there was a decrease in visceral fat 
imaged by MRI in addition to improved glucose tolerance as compared to the 
control group on high-fat diet.36 A genetic knockout of FSTL3 also showed 
several interesting results, including similar results to the over-expression model. 
The pancreatic islet sizes in the knockout mice were disproportionately large, 
leading to increased insulin concentrations. First believed that this was a sign of 
insulin resistance, a glucose tolerance test showed enhanced glucose tolerance 
tests.35  
FSTL3’s actions in the heart have also been explored, although not as 
extensively as whole-body targets. Through these experiments, FSTL3 was 
shown to promote LVH and cardiac fibrosis in models of pressure overload-
induced hypertrophy, ischemic injury, and β2 adrenergic agonist-induced 
hypertrophy.34 Both FSTL3 and activin A have been found to be regulated by 
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levels of stress in the heart, and were markedly upregulated following TAC after 
1 week.32  
The cardioprotective role of activin A is highlighted by Oshima et al. who 
injected a recombinant human activin A protein and witnessed a large reduction 
in infarct size following ischemia/reperfusion (I/R) injury.32 The opposing actions 
of FSTL3 on activin A were demonstrated by Shimano et al., who generated 
FSTL3 knockout (KO) mice.13 These KO mice showed reduced cardiac 
hypertrophy, LV wall thickness and dilatation following TAC than control mice.13 
The role of FSTL3 on cardiac fibrosis has also been investigated. Panse 
et al. discovered that FSTL3 is necessary and sufficient to begin the process of 
cardiac fibrosis, although fully developed cardiac fibrosis requires additional 
factors.34 The interaction of the cardiokine FSTL3 and the components of the 
structure of the heart are shown in Figure 4. 
	13	
 
Figure 4. FSTL3’s effect on cardiac fibrosis and hypertrophy. FSTL3 
is secreted from cardiac myocytes and is thought to act in a paracrine 
manner to develop hypertrophy. In addition, FSTL3 acts upon fibroblasts 
to promote proliferation and increased expression of collagens. From 
Panse et al. 2012.34 
 
Interestingly, FSTL3 has been found to be upregulated in end-stage HF 
and correlated with disease severity.32,34 Initial findings from Tu show that FSTL3 
is correlated to parameters of HF including LV wall thickness and declining 
Discussion
Cardiac fibrosis is often seen as part of the remodelling
response of the hypertrophied myocardium, and many inter-
ventional studies have noted a simultaneous reduction or an
increase in both cardiac hypertrophy and fibrosis. In con-
trast, other studies have reported a differential regulation of
hypertrophy and fibrosis. TGF-β triggers distinct signals in
cardiomyocytes and fibroblasts to promote hypertrophy and
fibrosis, respectively [38]. Similarly, mice with constitutive
active PI3K or dominant negative PI3K in the heart showed
an increased or decreased cardiac size, respectively, without
any effect on fibrosis [39]. Cardiac-specific Fstl3 KO mice
displayed reduced interstitial collagen and cardiac remodel-
ling, which may be a direct effect of reduced hypertrophy
following pressure overload [14]. However, microarray
analysis in these mice suggested that FSTL3 may function
mainly by the modulation of extracellular matrix compo-
nents rather than hypertrophic mediators. Moreover, cardi-
omyocytes, being the main source of increased FSTL3 in the
stressed heart, suggested that FSTL3 may function through
autocrine and/or paracrine actions on other cell types in the
Fig. 5 FSTL3 interacts with
CTGF. a CTGF was
immunoprecipitated from
fibroblast cell lysate using anti-
CTGF antibody and the bound
proteins detected by Western
blot. b Fibroblasts were stimu-
lated for 24 h with 200 ng/mL
FSTL3, 500 ng/mL CTGF or
both in serum-free medium, and
BrdU incorporation during the
last 18 h was measured to de-
termine cell proliferation. *p<
0.05 stimulus vs. control, un-
paired t test (n04). c Cells were
stimulated for 24 h as in (b) and
the Col1a1 mRNA expression
analysed by qRT-PCR. d
FSTL3 and CTGF expressions
were determined by qRT-PCR
in myocardial samples from
heart failure patients (n018),
and Spearman correlation be-
tween both factors was
calculated
Fig. 6 Schematic of FSTL3
action in the heart. FSTL3 is
secreted from cardiomyocytes
following mechanical loading
and acts in an autocrine manner
to induce cardiomyocyte
hypertrophy. In coordination
with unknown stretch-induced
factors, FSTL3 acts in a para-
crine manner on fibroblasts to
promote collagen synthesis. In
addition, FSTL3 interacts with
CTGF to enhance fibroblast
proliferation. Together, these
results suggest a role of FSTL3
in paracrine fibroblast
activation
822 J. of Cardiovasc. Trans. Res. (2012) 5:814–826
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diastolic function in instances of MetS.17 Using plasma from 63 patients 
diagnosed with MetS, and 14 control patients, the plasma levels of FSTL3 was 
significantly increased in patients with low mitral annular myocardial diastolic 
velocity (Em) and left ventricular hypertrophy (Figure 5).17 While this certainly 
doesn’t speak to the role of FSTL3 in cardiac remodeling, it does suggest it could 
be included in the pathway. 
Through these experiments, it appears that FSTL3 is involved in the 
regulation of cardiac fibrosis and hypertrophy following pressure overload. While 
pressure overload and MHD have several features in common, it is important to 
determine the role of FLRG in MHD.  
 
	15	
 
  
Figure 5. Plasma levels of FSTL3 correlated with diastolic function 
and LVH. These scatter plots show the correlation between plasma levels 
of FSTL3 and EM and LVH in certain human subjects. A) Higher levels of 
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FSTL3 are correlated (r2=0.13, p=0.002) with lower values of Em indicating 
diastolic dysfunction in patients with metabolic syndrome. B) Higher levels 
of FSTL3 are also seen with higher values of LVH, indicating the level of 
FSTL3 is indicative of structural change in the heart. Figures from Tu 
2015.17 
 
Specific Aims and Objectives 
The purpose of this study is evaluate the impact of the genetic ablation of 
a potential mediator of cardiac remodeling to determine its effect in a HFHS diet-
induced obesity model of metabolic syndrome. The hypothesis for this project is 
that the genetic ablation of FLRG will prevent the hypertrophy and fibrosis that is 
associated with a HFHS diet and metabolic syndrome.  
Understanding the development of cardiac hypertrophy and fibrosis in 
diet-induced MHD is an important milestone to get closer to early treatment of 
MHD and HF. By identifying the cardiokines that are the most influential on 
cardiac remodeling, there is potential for therapeutics to delay, or prevent, the 
development of cardiac remodeling that eventually leads to diastolic dysfunction, 
heart failure, and mortality. Through these experiments, we hope to: 
• Test whether HFHS diet-induced cardiac hypertrophy is prevented by a 
knockout of FSTL3 in cardiac myocytes. 
• Test whether HFHS diet-induced myocardial fibrosis is prevented by 
cardiac myocyte-specific FSTL3 KO.	
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METHODS 
 
HFHS diet mouse model of MetS and MHD 
 To accurately demonstrate the effect of diet on MHD, a HFHS diet model 
was used. A HFHS diet has been found to show to the same clinical features of 
MetS, including obesity, high fasting plasma glucose, and hypertension.20,21 In 
addition, a HFHS model of MetS has been shown to lead to a cardiac phenotype 
of MHD, including left ventricular hypertrophy, diastolic dysfunction, and 
interstitial fibrosis, all of which are critical to the purpose of this project.37,38 
Twenty-four CL57BL/6 mice were fed a HFHS diet for 5 months beginning at two 
months of age, which is standard for the HFHS diet model of MHD.  
 
FSTL3 KO mouse model 
To investigate the role of the FSTL3 KO in particular, a Cre-Lox method 
was used to delete exons 3-5 in a cardiomyocyte-specific method. 13 To obtain 
the desired cardiomyocyte-specific FSTL KO, female homozygous Fstl3flox/flox 
were crossed with male mice heterozygous for overexpressed Cre-recombinase 
promoted by the α-myosin heavy chain promoter (α-MHC-Cre). These mice had 
the C57BL/6 background and were obtained from The Jackson Laboratory. To 
ascertain the genotype of the progeny, tail snips from the mice were digested 
using the REDExtract-N-Amp™ Tissue PCR Kit (Sigma) to extract the genomic 
DNA. The DNA products were then multiplied using the polymerase chain 
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reaction (PCR). This PCR protocol consisted of an annealing temperature of 
56oC and ran for 40 cycles.17 To detect the knockout of FSTL3, the following loxP 
site-specific primer pair was used: 
 
SJL 954 5’-TCTGAGAAGAGGAGGGATTTCAAG-3’  
SJL 955 5’-ATTTACACCTAGCCACATACTCTG-3’  
 
The wild type allele produces a 270-bp fragment while the loxP site generates a 
310-bp fragment.32 To test for cardiomyocyte-specific knockout of FSTL3, the 
heart specific α-MHC-Cre transgene was detected with the following primers: 
9543 Fwd 5’-ATGACAGACAGATCCCTCCTATCTCC-3’  
9544 Rev 5’-CTCATCACTCGTTGCATCATCGAC-3’  
 
In addition, an internal control was used to detect the presence of DNA. These 
are the primers to bind to the T-cell receptor delta locus (Tcrd): 
  oIMR8744 iFwd 5’-CAAATGTTGCTTGTCTGGTG-3’  
oIMR8745 iRev 5’-GTCAGTCGAGTGCACAGTTT-3’  
 
The PCR products were then run on a 2% agarose gel and 0.01% GelRed™ 
nucleic acid stain (Biotium) using electrophoresis. The resulting fragment bands 
can be seen in Figure 6. 
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Figure 6. Genotyping FLRG KO mice.  Using PCR, the genotype of 
each mouse was determined to ensure the correct genetic manipulation 
was used for the experiment. A) Shows bands for FLRG KO vs. WT allele 
to determine the status of the floxed allele. B) Bands showing expression 
of α-MHC Cre. The internal control is a combination of the forward and 
reverse primers for Tcrd, T-cell receptor delta, which is endogeneous in all 
mice. 
The breeding strategy shown in Figure 7 was used to generate Fstl3flox/flox, Cre+/-. 
F/F,	CRE-/-	 WT,	CRE+/-	
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After three generations, the desired genotype of Fstl3flox/flox; Cre+/- was available 
(See Figure 7). These mice were then put on a high-fat, high-sucrose diet or a 
control diet for five months. Mice were then sacrificed and whole heart tissue was 
collected, placed on cold phosphate buffered saline (PBS, Bio-Rad) on ice, cut 
into three to four pieces, and snap frozen using liquid nitrogen. Prior to freezing 
the tissue, a small piece of the heart tissue was placed in a 10% formalin solution 
(Sigma) for 24 hours and, using an EDTA-coated pipette tip, a blood sample was 
taken from the chest cavity and placed into a separate EDTA-coated BD 
Microtainer®. 
	21	
 
 
 
Figure 7. Breeding strategy for FSTL3 KO mice. Mice were bred so that 
they progeny would be homozygous for FSTL3 KO, and hemizygous for α-
MHC-Cre or α-MHC-Cre-/-. Figure from Tu V. Dissertation, BU. 2015.  
Plasma Collection 
 
 Upon collection of a blood sample from the chest cavity of the mice, the 
EDTA-coated tubes were placed on ice until all samples were collected. These 
blood samples were then centrifuged at 4,615 rpm at room temperature for five 
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Figure 6 Fstl3 knockout breedin  strategy 
Mouse breeding strategy to generate cardiomyocyte-specific knockout of Fstl3.  
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-/-
 Fstl3
flox/flox
; Cre
+/-
 
 
X Fstl3
flox/flox
; Cre
-/-
 
Second Generation:       
           25%              25%               25%                 25% 
 
Third Generation:     50%                            50% 
Fstl3
floxflox
; Cre
+/-
 Fstl3
floxflox
; Cre
-/-
 
4 months of HFHS or CD 
diet feeding 5	months	of	HFHS	or	CD	feeding	
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minutes to form a loose pellet of cellular debris. The supernatant was then 
extracted and placed in a new 1.5 mL Eppendorf microcentrifuge tube. This 
supernatant was centrifuged again at 20,000 rpm for 15 minutes at room 
temperature. The supernatant (plasma) was collected, placed in a new, labeled 
1.5 mL Eppendorf microcentrifuge tube, dipped into liquid nitrogen to snap freeze 
the sample, then stored at -80oC. 
 
Histology Preparation 
 
 The small samples of heart tissues placed in formalin during the heart 
tissue collection were left to sit for 24 hours at room temperature. Then, the 
formalin was removed, and replaced with 1X PBS (Bio-Rad). The samples were 
then embedded in paraffin and sectioned with a microtome to produce 4 µm thick 
sections that were then placed in a warm water bath. The sections were 
positioned on labeled, positively charged glass slides and left to dry overnight. 
 
Picrosirius Red Staining for Fibrosis 
 
 The dried slides of tissue sections were rehydrated with xylene and 
ethanol baths in decreasing concentrations of 100%, 95% for 10 minutes each, 
and 80% and 70% for five minutes each. The slides were placed in Bouin’s 
Fixitave (Polysciences) that had been prewarmed to 55oC and allowed to sit in 
the 55oC water bath for 1 hour. The samples were then removed and washed 
with tap water for approximately 10 minutes, or until the visible yellow stain from 
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the Bouin’s washed away. The slides were then placed in Wiegert’s Iron 
Hemotoxylin (Sigma) for 7 minutes, then removed and washed again with tap 
water for another 10 minutes. The sections were then placed in the Picrosirius 
Red A solution (Polysciences) at room temperature for 2 minutes, rinsed with 
distilled water, then stained with Picrosirius Red B solution (Polysciences) for 1 
hour at room temperature. Before the dehydration process, the excess 
Picrosirius Red solution was wiped away from the slides. The sections were then 
dehydrated using ascending concentrations of ethanol of 95%, and 100% for 5 
seconds in each, then were cleared with xylene.  The dehydrated sections were 
then mounted using Eukitt quick-hardening mounting medium (Fluka Analytical) 
and left to dry overnight. The images were captured using an Olympus BX 40 
microscope on 20x magnification. Analysis was done using histology sections. 
About 6-8 sections were obtained from each animal’s heart. Then, about 2-3 
fields of view from each section were imaged to use for analysis. The limited 
amount of fields of view from some of the samples prevented extensive analysis. 
Therefore, a maximum of 13 fields of view were quantified. The amount of 
fibrosis identified with the Picrosirius Red stain was quantified using ImageJ 
(NIH, Bethesda, MD). 
 
Hematoxylin and Eosin Staining for Hypertrophy 
 
 The tissue sections were rehydrated with 15 minutes of a xylene bath, 
then 10 minutes each of descending ethanol concentrations of 100% and 95%, 
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then 5 minutes each of 80% and 70%. The slides were then rinsed with distilled 
water for 2 minutes. The slides were then stained with hematoxylin (Vector) for 5 
minutes, washed with tap water for 5 minutes, placed in 95% ethanol for 30 
seconds, and then stained with eosin (Sigma) for 3 minutes. The slides were 
then dehydrated with ascending concentrations of ethanol of 95% and 100%, and 
were then placed in 3 baths of xylene for 5 minutes each. Tissue sections were 
mounted using Eukitt quick-hardening mounting medium (Fluka Analytical) and 
left to dry overnight. The images were captured using an Olympus BX 40 
microscope on 40x magnification. Analysis was done using histology sections. 
Approximately 8-10 sections were obtained from each animal’s heart. Then, 
about 10-15 different fields of view from each section were imaged, and the cells 
with clear cell membranes and centered nuclei were used for measurements. 
Each heart provided anywhere from 30-70 myocytes for measurements. The 
diameter of cardiomyocytes was measured using ImageJ (NIH, Bethesda, MD).  
Statistical Analysis 
Results are displayed as mean ± SEM. Differences among groups were 
tested using unpaired, non-parametric Mann-Whitney t-tests. Due to the low 
sample sizes in the groups, non-Gaussian distribution was assumed in all of the 
calculations. Statistical analyses were executed using GraphPad Prism version 5 
(GraphPad Software, Inc.). Statistical significance was identified with a p-value < 
0.05. 
	25	
 RESULTS 	
FLRG KO had no apparent impact on weight gain or heart development 
 Over the course of the experiment, all animals were weighed monthly to 
track progress. A total of 23 mice were followed in this experiment, with four mice 
in the WT CD group, five mice in the WT HFHS diet group, five mice in the FLRG 
KO CD group, and nine mice in the FLRG KO HFHS diet group. Each heart 
generated approximately 8-10 sections for histology that were 4 µm thick. Diet-
induced weight gain was not affected by FLRG KO (Figure 8). The HFHS diet-fed 
groups gained the expected amount of weight after five months on diet (Figure 
9). 
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Figure 8. Mice gained weight over time. This chart shows body weight 
(in grams) gained by the animals over time. All animals gained similar 
amounts of weight; however, the FLRG KO groups gained less weight in 
both diet groups. There was statistical significance between every group 
(p<0.05).  
 
 
 
Figure 9. Percent change in body weight after five months on diet. 
HFHS diet groups gained weight (vs. CD fed) and the weight gain was not 
affect by FLRG KO. The asterisk indicated statistical significance 
compared to WT CD, with a p-value < 0.05. 
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Upon completion of the diet portion of this study, the hearts were weighed 
to get the raw heart weight for each animal (Figure 10), and then compared 
separately with each animal’s respective tibia length to normalize the body 
weight. There were four hearts in the WT CD group, five hearts in the WT HFHS, 
five hearts in the FLRG KO CD group, and nine hearts in the FLRG KO HFHS 
group. HW/tibia length seemed to be lower in FLRG KO HFHS mice than the WT 
HFHS group; however, this result was not statistically significant (p=0.10) 
(Figures 11 and 12).  
 
 
Figure 10. Heart weights. This figure displays the average heart weight 
for each animals group. The FLRG KO HFHS was statistically different 
from the WT HFHS, suggesting that a knockout of FLRG would help to 
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protect from the extent of hypertrophy seen in the WT HFHS diet fed 
group. 
 
 
Figure 11. Individual heart weight/tibia length. This figure shows the 
individual data points for each heart weight/tibia length from each mouse 
in the study. 
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Figure 12. Heart weight/tibia length for all groups. This chart shows no 
difference between all of the groups. However, there is a slight trend for 
the FLRG KO HFHS heart weight/tibia length to be slightly lower than the 
WT HFHS group (p=0.10). 
 
FLRG KO attenuated cardiomyocyte hypertrophy 
Following five months on a HFHS diet, WT cardiac myocytes in the HFHS-
fed group were larger (131%) than in WT CD-fed mice. The ablation of FLRG 
attenuated the extent of hypertrophy seen in HFHS-fed wild-type mice (Figures 
13, 14, and 15). Although there was still hypertrophy of the cardiomyocytes, the 
extent of the hypertrophy seen in the FLRG KO HFHS group (mean 
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cardiomyocyte diameter = 20.29 ± 0.23) was significantly different than that seen 
in the WT HFHS group (mean cardiomyocyte diameter = 21.76 ± 0.34).  	
 
Figure 13. Microscopy of cardiac myocyte hypertrophy. These four 
images show sections of heart tissue sections. The size differences in 
diameter between all four experimental groups are shown in the slides. 
Although the differences are most easily seen between the control diet 
and HFHS groups, the hypertrophy in the FLRG KO HFHS is significantly 
different than that in the WT HFHS group. All images show heart tissue 
stained with hematoxylin and eosin. Images captured at 40X 
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magnification. A) WT CD B) WT HFHS C) FLRG KO CD D) FLRG KO 
HFHS 
 
Figure 14. Individual cardiac myocyte measurements. This figure 
shows the individual cardiac myocyte diameter measurements for all 
mouse hearts in the experimental study. 
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Figure 15. Mean diameter of cardiomyocytes. The mean diameter of 
the cardiomyocytes between the WT HFHS group and FLRG KO HFHS 
group are both significantly different from the WT CD group with p-values 
of <0.0001 in each group. In addition, the FLRG KO protected the 
cardiomyocytes from the full extent of the hypertrophy seen in the WT 
HFHS (p=0.0009). The asterisk indicates a statistically significant 
difference between the indicated group and the WT CD group. The pound 
sign indicates a statistically significant difference between the WT HFHS 
and FLRG KO HFHS groups. 
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FLRG KO induced more fibrosis 	 To further explore the cardiac remodeling in a FLRG KO during a HFHS 
diet, cardiac interstitial fibrosis was imaged and quantitated (Figure 16). In WT 
CD-fed mice there was approximately 1.5% fibrosis. Following five months on a 
HFHS diet, this was increased to around 2%. With CD feeding, fibrosis was 
increased in FLRG mice relative to WT mice.  Likewise with HFHS feeding 
fibrosis was increased in FLRG vs. WT mice.  	
	
	34	
Figure 16. Microscopy of cardiac interstitial fibrosis. These four 
images show the difference in fibrosis between all four experimental 
groups. Collagen shows as red with this particular stain. Images were 
captured at 20x and analyzed with ImageJ. All images show heart tissue 
stained with picrosirius red. A) WT CD B) WT HFHS C) FLRG KO CD D) 
FLRG KO HFHS 
 
Figure 17. Individual fibrosis data. This figure shows the thirteen 
individual cardiac interstitial fibrosis measurements for all mouse hearts in 
the experimental study. 
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Figure 18. Mean percentage of interstitial fibrosis. Both the FLRG KO 
control diet group and the FLRG KO HFHS diet group showed increased 
interstitial fibrosis following five months on diet as compared to the WT CD 
group. The p-value between the control diet groups is 0.024, and the p-
value between the HFHS groups is <0.0001. The asterisk shows statistical 
significance between the group identified and the WT CD group. The 
pound sign indicates statistical significance between the WT HFHS and 
FLRG KO HFHS group.		  
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DISCUSSION 	
The interactions between FSTL3 and members of the TGF-β family, such 
as TGF-β1 and activin A, have been investigated to discover more about their 
roles in cardiac remodeling. Previous studies have shown that whole body 
knockouts and overexpressions of FSTL3 lead to dramatic improvements in 
endocrine function as related to insulin resistance and visceral fat deposition.35,36 
In studies of I/R injury and pressure overload, cardiac-specific knockout of FSTL3 
has shown to be cardioprotective in that activin A can induce its effects via the 
SMAD pathway to prevent hypertrophy after TAC, and also prevent apoptosis in 
cultured cardiac myocytes.13,32  
Myocardial hypertrophy. The attenuated hypertrophy seen with the FLRG 
KO group matches the notion from past research that a cardiac-specific ablation 
of FLRG is beneficial. All of the past studies involved with cardiomyocyte specific 
ablation of FLRG are related to the study of TAC, or pressure overload.13 Since 
we expected the mice in our study to develop metabolic syndrome, including 
hypertension, after five months on a HFHS diet, the attenuated hypertrophy is not 
surprising. As it relates to our hypothesis, however, we believed the FLRG KO 
would prevent the hypertrophy. In fact, the FLRG KO did attenuate the extent of 
hypertrophy seen in FLRG KO HFHS mice. 
 Fibrosis.  We observed the expected increase in fibrosis with HFHS in the 
wild-type group. Surprisingly, there was an increase in fibrosis in the FLRG KO 
CD and HFHS diet groups compared to their respective WT counterparts. 
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In both CD and HFHS-fed mice the FLRG KO groups had a striking 
increase in fibrosis compared to their WT counterparts. This is in contrast to the 
hypothesized decrease in fibrosis with FLRG KO, and furthermore, is in contrast 
to the decrease in myocyte hypertrophy observed with FLRG KO. While the 
reasoning is unknown we can speculate on certain possible causes. 
A potential pathway that could explain these results come from two known 
mediators in cardiac remodeling: FSTL3 and members of the TGF-β family. It has 
been shown that FSTL3 is an antagonizer of members of the TGF-β superfamily, 
including TGF-β1 and activin A. With a reduction in the amount of antagonizing 
effects of FSTL3 on these two components, each can influence cardiac 
remodeling in their respective ways. Several studies have shown TGF-β1’s role 
in heart failure and cardiac fibrogenesis.26,28,29,39,40 Without the negative regulator 
of TGF-β, it leaves TGF-β1 to promote collagen deposition.  
The potential pathway for the attenuated hypertrophy consists of activin 
A’s cardioprotective action to prevent hypertrophy and apoptosis in stressed the 
stressed heart.23,32 Without FSTL3, the negative regulator of activin A, the 
cardioprotective SMAD 2 signalling pathway would be increasingly active, which 
would lead to attenuated hypertrophy. 
 Limitations. The HFHS diet induced increase in HW/tibia length was not 
significant, although the trend between the WT HFHS and FLRG KO HFHS was 
strong (p=0.1). This may reflect low numbers or could have been a result of 
experimenter error while trimming the atria off of the heart after excision. Any 
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additional, unneeded tissue that was removed from the heart could have 
impacted the heart weight, and led to inaccurate results. However, myocyte size 
measured with histology showed the expected increase with HFHS diet, 
suggesting that there was cardiac hypertrophy. 
 A second limitation of this study was that the HFHS diet mice did not 
develop as much fibrosis as expected. This could be due to several factors, 
however. For example, there were small sample sizes in this project, with the WT 
CD group only having four viable animals, and five animals each in the WT 
HFHS and FLRG KO CD group. In doing our statistical analysis, we assumed 
non-Gaussian distribution to help correct for this, although the impact to the 
analysis is still present. In addition, there could have been errors in the 
quantification of the fibrosis using ImageJ. There are still many subjective 
decisions to be made regarding the closeness of the quantitated image as 
compared to the original image captured from the microscope. 
 Conclusion. This study was the first to test the role of FLRG in MHD using 
a cardiac-myocyte-specific FLRG KO mouse. The major new finding is that 
FLRG appears to mediate cardiac myocyte hypertrophy in MHD. Conclusions 
regarding the role of FLRG in fibrosis were not possible due to the lack of a 
change in the WT HFHS-fed group. Knowledge of the mechanism of cardiac 
fibrogenesis and hypertrophy in a model of metabolic syndrome could prove 
extremely beneficial to determine the early signs of heart failure in obese men 
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and women with metabolic syndrome and lead to early treatment and, perhaps 
eventually, prevention of heart failure due to metabolic heart disease. 	  
	40	
LIST OF JOURNAL ABBREVIATIONS 
 
Am J Cardiol. ....................................................... American Journal of Cardiology 
Am J Physiol - Cell Physiol. .... American Journal of Physiology – Cell Physiology 
Arterioscler Thromb Vasc Biol. ......................... Arteriosclerosis, Thrombosis, and 
Vascular Biology 
Cardiol Res Pract. ........................................... Cardiology Research and Practice 
Cell Mol Life Sci. .......................................... Cellular and Molecular Life Sciences 
Circ Cardiovasc Imaging ................................ Circulation Cardiovascular Imaging 
Circ Res. ............................................................................... Circulation Research 
Cytokine Growth Factor Rev. ......................... Cytokine & Growth Factor Reviews 
Eur Heart J. ...................................................................... European Heart Journal 
FASEB J. ................................................................................ The FASEB Journal 
Int J Cardiol ..................................................... International Journal of Cardiology 
J Am Coll Cardiol. ......................... Journal of the American College of Cardiology 
J Am Heart Assoc ............................... Journal of the American Heart Association 
JAMA ............................................... Journal of the American Medical Association 
J Biol Chem. ......................................................... Journal of Biological Chemistry 
J Card Fail .................................................................... Journal of Cardiac Failure 
J Cardiovasc Transl Res. ........ Journal of Cardiovascular Translational Research 
J Mol Cell Cardiol. ........................... Journal of Molecular and Cellular Cardiology 
Mol Genet Metab. ......................................... Molecular Genetics and Metabolism 
N Engl J Med .................................................... New England Journal of Medicine 
	41	
Pharmacol Ther .................................................. Pharmacology and Therapeutics 
Physiol Rev ........................................................................ Physiological Reviews 
Proc Natl Acad Sci. .................. Proceeding of the National Academy of Sciences 
Transl Res J Lab Clin Med. ..................... Translational Research, The Journal of 
Laboratory and Clinical Medicine 
  
	42	
REFERENCES 
1.  Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke 
Statistics—2015 Update A Report From the American Heart Association. 
Circulation. 2015;131(4):e29-e322. doi:10.1161/CIR.0000000000000152. 
2.  Lemieux I, Pascot A, Couillard C, et al. Hypertriglyceridemic Waist A Marker 
of the Atherogenic Metabolic Triad (Hyperinsulinemia; Hyperapolipoprotein 
B; Small, Dense LDL) in Men? Circulation. 2000;102(2):179-184. 
doi:10.1161/01.CIR.102.2.179. 
3.  Ervin RB. Prevalence of Metabolic Syndrome Among Adults 20 Years of 
Age and Over, by Sex, Age, Race and Ethnicity, and Body Mass Index: 
United States, 2003–2006. May 2009. 
http://www.cdc.gov/nchs/data/nhsr/nhsr013.pdf. Accessed August 28, 2015. 
4.  Perrone-Filardi P, Paolillo S, Costanzo P, Savarese G, Trimarco B, Bonow 
RO. The role of metabolic syndrome in heart failure. Eur Heart J. August 
2015:ehv350 - . doi:10.1093/eurheartj/ehv350. 
5.  About Metabolic Syndrome. 
http://www.heart.org/HEARTORG/Conditions/More/MetabolicSyndrome/Abo
ut-Metabolic-Syndrome_UCM_301920_Article.jsp. Accessed April 1, 2015. 
6.  Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, Participants  for 
the C. Definition of Metabolic Syndrome Report of the National Heart, Lung, 
and Blood Institute/American Heart Association Conference on Scientific 
Issues Related to Definition. Arterioscler Thromb Vasc Biol. 2004;24(2):e13-
e18. doi:10.1161/01.ATV.0000111245.75752.C6. 
7.  Mottillo S, Filion KB, Genest J, et al. The Metabolic Syndrome and 
Cardiovascular Risk: A Systematic Review and Meta-Analysis. J Am Coll 
Cardiol. 2010;56(14):1113-1132. doi:10.1016/j.jacc.2010.05.034. 
8.  Katz AM, Rolett EL. Heart failure: when form fails to follow function. Eur 
Heart J. October 2015:ehv548. doi:10.1093/eurheartj/ehv548. 
9.  Kenchaiah S, Evans JC, Levy D, et al. Obesity and the Risk of Heart Failure. 
N Engl J Med. 2002;347(5):305-313. doi:10.1056/NEJMoa020245. 
10.  Sverdlov AL, Elezaby A, Qin F, et al. Mitochondrial Reactive Oxygen 
Species Mediate Cardiac Structural, Functional, and Mitochondrial 
Consequences of Diet‐Induced Metabolic Heart Disease. J Am Heart Assoc. 
2016;5(1):e002555. doi:10.1161/JAHA.115.002555. 
	43	
11.  Ayalon N, Gopal DM, Mooney DM, et al. Preclinical Left Ventricular Diastolic 
Dysfunction in Metabolic Syndrome. Am J Cardiol. 2014;114(6):838-842. 
doi:10.1016/j.amjcard.2014.06.013. 
12.  Huynh K, Bernardo BC, McMullen JR, Ritchie RH. Diabetic cardiomyopathy: 
Mechanisms and new treatment strategies targeting antioxidant signaling 
pathways. Pharmacol Ther. 2014;142(3):375-415. 
doi:10.1016/j.pharmthera.2014.01.003. 
13.  Shimano M, Ouchi N, Nakamura K, et al. Cardiac myocyte-specific ablation 
of follistatin-like 3 attenuates stress-induced myocardial hypertrophy. J Biol 
Chem. 2011;286(11):9840-9848. doi:10.1074/jbc.M110.197079. 
14.  Kamo T, Akazawa H, Komuro I. Cardiac Nonmyocytes in the Hub of Cardiac 
Hypertrophy. Circ Res. 2015;117(1):89-98. 
doi:10.1161/CIRCRESAHA.117.305349. 
15.  Polyakova V, Loeffler I, Hein S, et al. Fibrosis in endstage human heart 
failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int 
J Cardiol. 2011;151(1):18-33. doi:10.1016/j.ijcard.2010.04.053. 
16.  Weber KT, Pick R, Jalil JE, Janicki JS, Carroll EP. Patterns of myocardial 
fibrosis. J Mol Cell Cardiol. 1989;21, Supplement 5:121-131. 
doi:10.1016/0022-2828(89)90778-5. 
17.  Tu VH. The role of cardiokines in metabolic heart disease. 2015. 
http://search.proquest.com/pqdtglobal/docview/1700848752/abstract/7B2A8
57AEF5942DBPQ/1?accountid=9676. Accessed August 19, 2015. 
18.  Moreo A, Ambrosio G, Chiara BD, et al. Influence of Myocardial Fibrosis on 
Left Ventricular Diastolic Function Noninvasive Assessment by Cardiac 
Magnetic Resonance and Echo. Circ Cardiovasc Imaging. 2009;2(6):437-
443. doi:10.1161/CIRCIMAGING.108.838367. 
19.  Redfield MM, Jacobsen SJ, Burnett, et al. Burden of systolic and diastolic 
ventricular dysfunction in the community: Appreciating the scope of the heart 
failure epidemic. JAMA. 2003;289(2):194-202. doi:10.1001/jama.289.2.194. 
20.  Qin F, Siwik DA, Luptak I, et al. The Polyphenols Resveratrol and S17834 
Prevent the Structural and Functional Sequelae of Diet-Induced Metabolic 
Heart Disease in Mice. Circulation. 2012;125(14):1757-1764. 
doi:10.1161/CIRCULATIONAHA.111.067801. 
	44	
21.  Weisbrod RM, Shiang T, Sayah LA, et al. Arterial Stiffening Precedes 
Systolic Hypertension in Diet-Induced Obesity. Hypertension. 
2013;62(6):1105-1110. doi:10.1161/HYPERTENSIONAHA.113.01744. 
22.  Abel ED, Litwin SE, Sweeney G. Cardiac Remodeling in Obesity. Physiol 
Rev. 2008;88(2):389-419. doi:10.1152/physrev.00017.2007. 
23.  Shimano M, Ouchi N, Walsh K. Cardiokines Recent Progress in Elucidating 
the Cardiac Secretome. Circulation. 2012;126(21):e327-e332. 
doi:10.1161/CIRCULATIONAHA.112.150656. 
24.  Maisel AS, Shah KS, Barnard D, et al. How B-Type Natriuretic Peptide 
(BNP) and Body Weight Changes Vary in Heart Failure with Preserved 
Ejection Fraction compared to Reduced Ejection Fraction: Secondary 
Results of the HABIT (HF Assessment with Bnp In The Home) Trial. J Card 
Fail. doi:10.1016/j.cardfail.2015.09.014. 
25.  Dobaczewski M, Chen W, Frangogiannis NG. Transforming growth factor 
(TGF)-β signaling in cardiac remodeling. J Mol Cell Cardiol. 2011;51(4):600-
606. doi:10.1016/j.yjmcc.2010.10.033. 
26.  Aihara K, Ikeda Y, Yagi S, et al. Transforming Growth Factor-β1 as a 
Common Target Molecule for Development of Cardiovascular Diseases, 
Renal Insufficiency and Metabolic Syndrome, Transforming Growth Factor-
β1 as a Common Target Molecule for Development of Cardiovascular 
Diseases, Renal Insufficiency and Metabolic Syndrome. Cardiol Res Pract. 
2010;2011, 2011:e175381. doi:10.4061/2011/175381, 
10.4061/2011/175381. 
27.  Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-β by 
thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor 
Rev. 2000;11(1–2):59-69. doi:10.1016/S1359-6101(99)00029-5. 
28.  Lijnen PJ, Petrov VV, Fagard RH. Induction of Cardiac Fibrosis by 
Transforming Growth Factor-β1. Mol Genet Metab. 2000;71(1–2):418-435. 
doi:10.1006/mgme.2000.3032. 
29.  Biernacka A, Dobaczewski M, Frangogiannis NG. TGF-β signaling in 
fibrosis. Growth Factors. 2011;29(5):196-202. 
doi:10.3109/08977194.2011.595714. 
30.  Trendelenburg AU, Meyer A, Rohner D, Boyle J, Hatakeyama S, Glass DJ. 
Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast 
differentiation and myotube size. Am J Physiol - Cell Physiol. 
2009;296(6):C1258-C1270. doi:10.1152/ajpcell.00105.2009. 
	45	
31.  Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor 
for mortality in chronic heart failure. The Lancet. 1997;349(9058):1050-1053. 
doi:10.1016/S0140-6736(96)07015-8. 
32.  Oshima Y, Ouchi N, Shimano M, et al. Activin A and Follistatin-Like 3 
Determine the Susceptibility of Heart to Ischemic Injury. Circulation. 
2009;120(16):1606-1615. doi:10.1161/CIRCULATIONAHA.109.872200. 
33.  Mukherjee A, Sidis Y, Mahan A, et al. FSTL3 deletion reveals roles for TGF-
β family ligands in glucose and fat homeostasis in adults. Proc Natl Acad 
Sci. 2007;104(4):1348-1353. doi:10.1073/pnas.0607966104. 
34.  Panse KD, Felkin LE, López-Olañeta MM, et al. Follistatin-Like 3 Mediates 
Paracrine Fibroblast Activation by Cardiomyocytes. J Cardiovasc Transl 
Res. 2012;5(6):814-826. doi:10.1007/s12265-012-9400-9. 
35.  Mukherjee A, Sidis Y, Mahan A, et al. FSTL3 deletion reveals roles for TGF-
beta family ligands in glucose and fat homeostasis in adults. Proc Natl Acad 
Sci U S A. 2007;104(4):1348-1353. doi:10.1073/pnas.0607966104. 
36.  Brandt C, Hansen RH, Hansen JB, et al. Over-expression of Follistatin-like 3 
attenuates fat accumulation and improves insulin sensitivity in mice. 
Metabolism. 2015;64(2):283-295. doi:10.1016/j.metabol.2014.10.007. 
37.  Sverdlov AL, Elezaby A, Behring JB, et al. High fat, high sucrose diet causes 
cardiac mitochondrial dysfunction due in part to oxidative post-translational 
modification of mitochondrial complex II. J Mol Cell Cardiol. 2015;78:165-
173. doi:10.1016/j.yjmcc.2014.07.018. 
38.  Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, 
and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, 
and therapeutic opportunities. Transl Res J Lab Clin Med. 2014;164(4):323-
335. doi:10.1016/j.trsl.2014.05.001. 
39.  Leask A, Abraham DJ. TGF-β signaling and the fibrotic response. FASEB J. 
2004;18(7):816-827. doi:10.1096/fj.03-1273rev. 
40.  Lim H, Zhu YZ. Role of transforming growth factor-beta in the progression of 
heart failure. Cell Mol Life Sci CMLS. 2006;63(22):2584-2596. 
doi:10.1007/s00018-006-6085-8. 
 
  
	46	
CURRICULUM VITAE 
WILLIAM LONG 
 
120 Boylston St. 
Boston, MA 02116 
(303) 886-7317 
wplong@bu.edu 
Year of Birth - 1990 
 
EDUCATION 
 
M.S. in Medical Science    Anticipated 2016 
Boston University School of Medicine, Boston, MA   
 
B.S. in Biology, cum laude    May 2012  
Regis University, Denver, CO 
 
 
 
Research Experience 
 
Whitaker Cardiovascular Center, Boston University School of Medicine 
Research Assistant – Master of Science Thesis, July 2015 – May 2016 
• Planned and implemented an independent project detailing the role of 
FSTL3 in cardiac hypertrophy and fibrosis in metabolic syndrome. 
• Updated the lab manager regularly using presentations at weekly lab 
meetings. 
• Collected all samples for analysis using carefully organized plans, and 
detailed notes. 
• Conducted histological preparation and staining procedures using 
picrosirius red, hematoxylin, and eosin. 
• Analyzed all data for statistical significance using Friedman, Wilcoxon, 
Kruskal-Wallis, and Mann-Whitney tests. 
National Renewable Energy Laboratory, Golden, CO 
Internship in Microalgal Biofuels, August 2011 – May 2013 
• Performed detailed chemical analysis on algae samples using a variety of 
solvents and laboratory instruments 
• Recorded detailed results of fatty acid methylated ester (FAME) analysis, 
optical density, and soxhlet extractions 
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• Established a firm foundation in basic biological science research while 
strengthening work ethic by working in a professional environment and 
government lab 
 
Regis University, Denver, CO  
Lab Research Assistant – Ichthyology, June 2010 – August 2010 
• Recorded anatomical characteristics of fish skeletal systems resulting in a 
new, updated phylogenetic tree 
• Interpreted results using the computer program MacClade 
 
Clinical Experience 
 
Penrose Hospital, Colorado Springs, CO 
Patient Transport Aide, June 2013 – June 2014 
• Served patients by transporting them to schedule appointments in various 
departments throughout the hospital 
• Oversaw the logistics of oxygen transportation throughout the hospital 
• Ensured sanitization of transportation vehicles 
 
Penrose Hospital, Colorado Springs, CO 
Physician Shadowing – Hospitalist, August 2013 – January 2014 
• Observed the general and administrative responsibilities of an internist 
involved with patient care 
• Interacted with other health care professionals (e.g. physicians, nurses, 
respiratory therapists, case managers, etc.) and observed their roles in 
patient care 
 
University of Colorado Cancer Center, Aurora, CO  
Clinical Research Assistant, May 2011 – August 2011 
• Conducted follow-up interviews with patients who had participated in 
clinical trials for cancer treatment regarding their preset condition and 
updated their file accordingly 
• Attained experience with the role of planning, budgeting, and follow-up 
care associated with a formal research study 
 
 
Other Work Experience 
 
Regis University, Denver, CO 
Writing Consultant, January 2009 – May 2012 
• Provided students critical feedback regarding written works, specifically on 
topics of grammar, organization, formatting, and research practices 
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• Coached students on professional accepting and using constructive 
criticism and feedback, as needed 
 
Regis University, Office of Residence Life, Denver, CO  
Resident Assistant, August 2009 – May 2011 
• Designed programs that contributed to a healthy floor community and 
learning opportunities for students 
• Counseled residents in dealing with personal and academic issues 
• Served as a first responder to emergency situations on-campus 
 
 
 
Significant Coursework Experience 
 
Denver Health Medical Center, Denver, CO 
Clinical Trial Enrollment Assistant, September 2010 – December 2010 
• As part of the Biomedical Clinical Research course at Denver Health 
Medical Center, learned steps involved in planning, implementing, and 
statistically analyzing clinical research data. 
• Gained teamwork experience in a medical setting while enrolling patients 
into ongoing clinical studies at the hospital. 
 
